{"url_path":"/sec/inbx/8-k/2026-06-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000033-index.html","accession_number":"0002007919-26-000033","cik":"0002007919","ticker":"INBX","issuer_name":"Inhibrx Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000033-index.html","primary_entity_key":"0002007919","primary_entity_name":"Inhibrx Biosciences, Inc."},"word_count":58,"has_tables":true,"body_markdown":"Item 8.01. Other Events.\n\nOn June 15, 2026, the Company announced that the FDA has accepted for filing its BLA seeking approval of ozekibart for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. The FDA has not identified any filing review issues at this time and has assigned a PDUFA goal date of April 14, 2027."}